Your session is about to expire
← Back to Search
Study Summary
This trial evaluates a new treatment (AVB-001) for ovarian cancer, which is delivered IP to patients. It tests safety and efficacy of a single dose.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had 5 or fewer previous cancer treatments.My cancer is a type that started in the ovary, peritoneum, or fallopian tube and cannot be removed or treated with platinum-based chemotherapy.I may have had treatments like immunotherapy or targeted therapy for my cancer.I am fully active or restricted in physically strenuous activity but can do light work.I can give or have someone who can give consent for me.You have signs of the disease that can be seen on a CT or MRI scan.Your blood tests must show: a normal level of white blood cells, a certain level of hemoglobin, a certain level of platelets, good kidney function, and normal levels of certain liver enzymes and blood clotting factors.I haven't had cancer, except for certain skin, cervical, or breast conditions, in the last 3 years.I can stop my blood thinner medication for surgery if needed.You are allergic to AVB-001 or any of its ingredients, like alginate or seaweed.I may have been treated with PARP inhibitors, immunotherapy, or other specific therapies.My cancer has spread to the pleural cavity or other distant areas but can be measured in the IP cavity.My cancer is a specific type affecting the ovary, peritoneum, or fallopian tube.
- Group 1: Part 1 escalating AVB-001 between 0.6 and 3.6 ug hIL-2/kg/day; and Part 2 AVB-001 at the MTD/RP2D
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the maximum number of participants eligible for this scientific experiment?
"Affirmative. According to the clinicaltrials.gov database, this trial is currently recruiting volunteers. It was first posted on November 1st 2022 and recently updated on November 22nd 2022; 44 people are needed from one site for full participation in the study."
Are individuals still able to join this ongoing experiment?
"Affirmative, clinicaltrials.gov confirms that this trial is actively enrolling patients. It was first publicized on November 1st 2022 and has undergone recent edits as of the 22nd of November in said year. A total of 44 participants are being recruited for a single location."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger